Exploring the cost-effectiveness of Albumin-enhanced IV crystalloids in sepsis fluid resuscitation

Mohamed Metwally Mosly, Hesham Metwalli Mousli, Iman Mohamed Momtaz Ahmed, Mohamed Ibrahim Affify Abdou

Abstract


Background:  This study aims to evaluate the cost-effectiveness of using albumin as well as crystalloids compared to the baseline use of crystalloids alone in the management of sepsis in the context of the Egyptian healthcare system. crucial for healthcare policymakers and managers, particularly in settings where reasonable cost containment is a priority.

Methods: A decision tree model was created using TreeAge Healthcare Pro® software to compare two treatment groups for patients with severe sepsis or septic shock: one receiving only crystalloid fluids and the other receiving both crystalloid fluids and human albumin. The treatments were compared using the Incremental Cost-Effectiveness Ratio (ICER) and Net Monetary Benefit (NMB). Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the results.

Results: Although comparing the cost-effectiveness of both alternatives showed an ICER of 162,00 L.E in favor of the albumin plus crystalloids use in sepsis cases management, there was no dominance of either alternative over the other in terms of the cost-effectiveness plane.  By considering the NMB relevant to each individual alternative, the albumin plus crystalloids choice resulting in (-323,485 L.E) while the use of crystalloids alone resulting in higher NMB estimate of (-312,285 L.E). The results showed a considerable sensitivity to the cost of Albumin, the probabilistic sensitivity analysis showed robustness of the base case results over the estimated willingness to pay threshold of 160,000 L.E.

Conclusions: The study showed that albumin-based management of sepsis and septic shoch patients is not a cost-effective choice up to the WTP threshold of 300,000 L.E.

 

Received: 04 July 2024

Accepted: 26 August 2024

Published: 19 September 2024


Keywords


Sepsis, Cost-Effectiveness, Albumin, Fluid, Egypt, Adult.

Full Text:

PDF

References


Howell MD, Davis AM. Management of Sepsis and Septic Shock. JAMA. 2017 Feb 28;317(8):847.

Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). Vol. 315, JAMA - Journal of the American Medical Association. 2016.

Vincent JL, Marshall JC, Ñamendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al. Assessment of the worldwide burden of critical illness: The Intensive Care Over Nations (ICON) audit. Lancet Respir Med. 2014;2(5).

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign. Crit Care Med. 2013 Feb;41(2):580–637.

Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: Global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2(1).

Angus DC, van der Poll T. Severe Sepsis and Septic Shock. New England Journal of Medicine. 2013 Aug 29;369(9):840–51.

Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Vol. 5, Virulence. 2014.

Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R, et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37(1).

Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin Replacement in Patients with Severe Sepsis or Septic Shock. New England Journal of Medicine. 2014;370(15).

Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for fluid resuscitation in patients with sepsis: A meta-analysis. PLoS One. 2014;9(12).

Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ. 2014 Jul 22;349(jul22 10):g4561–g4561.

Keeney S, Hasson F, Mckenna H. The Delphi Technique in Nursing and Health Research. The Delphi Technique in Nursing and Health Research. 2010.

Fayanju OM, Haukoos JS, Tseng JF. CHEERS Reporting Guidelines for Economic Evaluations. Vol. 156, JAMA Surgery. 2021.

Tchouaket Nguemeleu E, Boivin S, Robins S, Sia D, Kilpatrick K, Brousseau S, et al. Development and validation of a time and motion guide to assess the costs of prevention and control interventions for nosocomial infections: A Delphi method among experts. PLoS One. 2020 Nov 12;15(11):e0242212.

Birko S, Dove ES, Özdemir V, Dalal K. Evaluation of nine consensus indices in delphi foresight research and their dependency on delphi survey characteristics: A simulation study and debate on delphi design and interpretation. PLoS One. 2015;10(8).

Niederberger M, Köberich S. Coming to consensus: The Delphi technique. European Journal of Cardiovascular Nursing. 2021;20(7).

Tigabu B, Davari M, Kebriaeezadeh A, Mojtahedzadeh M, Sadeghi K, Jahangard-Rafsanjani Z. Is Albumin-based Resuscitation in Severe Sepsis and Septic Shock Justifiable? An Evidence from a Cost-effectiveness Evaluation. Ethiop J Health Sci. 2019;29(1).

Xu JY, Chen QH, Xie JF, Pan C, Liu SQ, Huang LW, et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: A meta-analysis of randomized clinical trials. Crit Care. 2014;18(6).

Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 1982;73(6).

Zethraeus N, Johannesson M, Jönsson B, Löthgren M, Tambour M. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Vol. 21, PharmacoEconomics. 2003.

Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. Pharmacoeconomics. 2021;39(1).

Iino H, Hashiguchi M, Hori S. Estimating the range of incremental costeffectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. Vol. 17, PLoS ONE. 2022.

Bank W. GDP (current US) | Data [Internet]. 2010. Available from: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=EG

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004 Mar;32(3):858–73.

Leisman DE, Doerfler ME, Schneider SM, Masick KD, D’Amore JA, D’Angelo JK. Predictors, prevalence, and outcomes of early crystalloid responsiveness among initially hypotensive patients with sepsis and septic shock. Crit Care Med. 2018;46(2).

Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12).

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov 2;47(11):1181–247.

Melia D, Post B. Human albumin solutions in intensive care: A review. Vol. 22, Journal of the Intensive Care Society. 2021.

Farrugia A, Bansal M, Balboni S, Kimber M, Martin G, Cassar J. Choice of Fluids in Severe Septic Patients - A Cost-effectiveness Analysis Informed by Recent Clinical Trials. Rev Recent Clin Trials. 2014;9(1).

Altawalbeh SM, Almestarihi EM, Khasawneh RA, Momany SM, Abu Hammour K, Shawaqfeh MS, et al. Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: a patient-level data analysis in Jordan. J Med Econ. 2024 Dec 31;27(1):126–33.

Guidet B, Mosqueda GJ, Priol G, Aegerter P. The COASST study: Cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care. 2007;22(3).

Malguid C. Direction Générale du Trésor et de la Politique Économique. Analyse économique de la prévention des risques pour la santé. Diagnostics Prévisions et Analyses Économiques. 2005;(71).




DOI: https://dx.doi.org/10.21622/AMPDR.2024.04.2.914

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Mohamed Metwally Mosly, Hesham Metwalli Mousli, Iman Mohamed Momtaz Ahmed, Mohamed Ibrahim Affify Abdou

Advances in Medical, Pharmaceutical and Dental Research
E-ISSN: 2812-4898
P-ISSN: 2812-488X 

Published by:

Academy Publishing Center (APC)
Arab Academy for Science, Technology and Maritime Transport (AASTMT)
Alexandria, Egypt
ampdr@aast.edu